Email this article TARGET IMMUNOTHERAPY IN SECONDARY IMMUNE DEFICIENCY WITH INFECTIOUS SYNDROME
- Authors: Nesterova I.V.1,2
-
Affiliations:
- Federal State Budget Educational Institution of Higher Education «Kuban State Medical University» of the Ministry of Health Development of Russia
- Federal State Autonomous Budget Educational Institution of Higher Professional Education «Peoples’ Friendship University of Russia» of Ministry of Education and Science of Russia
- Issue: Vol 22, No 4 (2019)
- Pages: 1512-1516
- Section: ORIGINAL ARTICLES
- Submitted: 29.10.2020
- Accepted: 29.10.2020
- Published: 20.12.2019
- URL: https://rusimmun.ru/jour/article/view/958
- DOI: https://doi.org/10.31857/S102872210007074-6
- ID: 958
Cite item
Full Text
Abstract
The main goal of this work is to highlight the current state of immunomodulatory therapy with targeted – targeted action, which is used effectively when conducting immunomodulatory therapy of secondary immunodeficiencies, provided that the immunomodulatory drug acts on a known receptor. For example, glucosaminylmuramipeptide acts through NOD2 or recombinant interferon alpha 2b with an antioxidant complex through the IFN alpha receptor. Modern data on targeted action drugs – monoclonal antibodies (monAT), currently used are given. The positive and negative effects of biologic therapy are described, as well as methods of preventing and preventing side effects. It has been suggested that in the future, in order to avoid errors and complications, monotherapy should be administered by clinical immunology (in collaboration with specialists from other fields of medicine) under the control of the immune system and interferon status.
About the authors
I. V. Nesterova
Federal State Budget Educational Institution of Higher Education «Kuban State Medical University» of the Ministry of Health Development of Russia;Federal State Autonomous Budget Educational Institution of Higher Professional Education «Peoples’ Friendship University of Russia» of Ministry of Education and Science of Russia
Author for correspondence.
Email: fake@neicon.ru
Chief Researcher of Central Research Laboratory, Krasnodar;
Doctor of Medical Sciences (MD), Professor, Professor of the Department of Allergology and Immunology, Moscow
Russian FederationReferences
- Нестерова И. В. Вторичные иммунодефициты и методы их коррекции в практике врачаоториноларинголога. «Иммунотерапия в практике ЛОР-врача и терапевта», под редакцией А. С. Симбирцева, Г. В. Лавреновой. Спб.: Диалог, 2018, 32–97.
- Нестерова И. В. Иммунотропные препараты и современная иммунотерапия в клинической иммунологии и медицине. Аллергология и иммунология, 2000, 23(3), 18–28.
- Tanaka T., Narazaki M., Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy, 2016, 8(8), 959–970.
- Van Ton A. M. P., Kox M., Abdo W. F., Pickkers P. Precision Immunotherapy for Sepsis. Frontiers In Immunology, 2018, https://doi.org/10.3389/fimmu.2018. 01926)).
- Castro M. G., Baker G. J., Lowenstein P. R. Blocking immunosuppressive checkpoints for glioma therapy: the more the merrier!. Clin Cancer Res., 2014, 20(20), 5147–5149.
- Kirkham B. W., Kavanaugh A., Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology, 2014, 141(2), 133–142. 7. Ballow M., Fleisher T. Secondary immunodeficiency induced by drugs and biologic therapies. UpToDate, 2015.https://www.uptodate.com/contents/secondaryimmunodeficiency-induced-by-biologic-therapies.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).